1
|
Sharif F, Rasul A, Ashraf A, Hussain G, Younis T, Sarfraz I, Chaudhry MA, Bukhari SA, Ji XY, Selamoglu Z, Ali M. Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy. IUBMB Life 2019; 71:1418-1427. [PMID: 31169978 DOI: 10.1002/iub.2100] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2019] [Accepted: 05/22/2019] [Indexed: 12/15/2022]
Abstract
Altered enzymatic machineries are a substantial biochemical characteristic of tumor cell metabolism that switch metabolic profile from oxidative phosphorylation to amplified glycolysis as well as increased lactate production under hypoxia conditions. Reprogrammed metabolic profile is an emerging hallmark of cancer. Overexpression of several glycolytic enzymes and glucose transporters has been reported in 24 different types of cancers that represent approximately 70% of all the cancer cases around the globe. Thus, targeting glycolytic enzymes could serve as tempting avenue for drug design against cancer. Phosphoglycerate mutase 1 (PGAM1) is an important glycolytic enzyme that catalyzes the conversion of 3-phosphoglycerate to 2-phosphoglycerate. Recent investigations have revealed the overexpression of PGAM1 in several human cancers that is linked with tumor growth, survival, and invasion. The aim of this review is to update scientific research network with cancer-specific role of PGAM1 to elucidate its capability as bonafide therapeutic target for cancer therapy. Moreover, we have also summarized the reported genetic and pharmacological inhibitors of PGAM1. This study suggests that further investigations on PGAM1 should focus on the exploration of molecular mechanisms of PGAM1 overexpression in development of cancer, assessment of biosafety profiles of known inhibitors of PGAM1, and utilization of PGAM1 inhibitors in combinatorial therapies. These future studies will surely support the unbiased strategies for the development of novel PGAM1 inhibitors for cancer therapies.
Collapse
Affiliation(s)
- Farzana Sharif
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Azhar Rasul
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Asma Ashraf
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Ghulam Hussain
- Department of Physiology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Tahira Younis
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Iqra Sarfraz
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Muhammad Asrar Chaudhry
- Department of Zoology, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Shazia A Bukhari
- Department of Biochemistry, Faculty of Life Sciences, Government College University Faisalabad (GCUF), Pakistan
| | - Xin Y Ji
- Henan International Joint Laboratory of Protein Regulation, College of Medicine, Henan University, Kaifeng, Henan, China
| | - Zeliha Selamoglu
- Department of Medical Biology, Faculty of Medicine, Nigde Ömer Halisdemir University, Turkey
| | | |
Collapse
|